EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

John H Stone, Frank Buttgereit iD, Alain Saraux, Wolfgang A Schmidt, Christian Dejaco, Robert Spiera iD, Bhaskar Dasgupta, Edit Drescher, Andrew Jordan, Libor Novosad, Daiki Nakagomi, Yoshinobu Koyama und 14 weitere

New England Journal of Medicine · 2026

DOI: 10.1056/nejmoa2602567 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von John H Stone und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Inflammation, and Immunology, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glucocorticoids, Interleukin-17, Polymyalgia Rheumatica. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlucocorticoidsInterleukin-17Polymyalgia RheumaticaAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Therapy, CombinationPrednisoneRecurrenceRemission InductionDrug Tapering

Substanzen

Antibodies, Monoclonal, HumanizedGlucocorticoidsInterleukin-17PrednisonesecukinumabIL17A protein, human

Autor:innen und Institutionen

  • Division of Rheumatology, Inflammation, and Immunology, Massachusetts General Hospital, Boston.
  • Division of Rheumatology, Inflammation, and Immunology, Harvard Medical School, Boston.
  • Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin.
  • Deutsches Rheuma-Forschungszentrum, Berlin.
  • Centre Hospitalier Universitaire Brest, Université de Bretagne Occidentale, INSERM Unité Mixte de Recherche 1227, Brest, France.
  • Department of Rheumatology, Waldfriede Hospital, Berlin.

ORCID-Profile: Frank Buttgereit, Robert Spiera

Förderung

  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Stone, J. H., Buttgereit, F., Saraux, A., Schmidt, W. A., Dejaco, C., Spiera, R., Dasgupta, B., Drescher, E., Jordan, A., Novosad, L., Nakagomi, D., Koyama, Y., Duran-Barragan, S., Tracey, G., Ruyssen-Witrand, A., Rubbert Roth, A., Fang, J., Ng, J., Hiremath, R., …, & REPLENISH Investigators (2026). Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2602567

Vancouver

Stone JH, Buttgereit F, Saraux A, Schmidt WA, Dejaco C, Spiera R, et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2602567

BibTeX
@article{Stone2026,
  author = {Stone, John H and Buttgereit, Frank and Saraux, Alain and Schmidt, Wolfgang A and Dejaco, Christian and Spiera, Robert and Dasgupta, Bhaskar and Drescher, Edit and Jordan, Andrew and Novosad, Libor and Nakagomi, Daiki and Koyama, Yoshinobu and Duran-Barragan, Sergio and Tracey, Gerald and Ruyssen-Witrand, Adeline and Rubbert Roth, Andrea and Fang, Juanzhi and Ng, Jennifer and Hiremath, Renuka and Raffner, Roselyne and Martin, Ruvie and Napoletano, Silvia and Huang, Songqiao and Storim, Julian and Patekar, Manmath and REPLENISH Investigators, REPLENISH Investigators},
  title = {Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2602567}
}
Kostenlos starten →